Alebund Pharmaceuticals, a renal-focused biopharmaceutical company, has entered into licensing and equity agreements with R1 Therapeutics Inc., a newly launched clinical-stage biotechnology company, under which R1 has been granted an exclusive license to develop, manufacture, and commercialize AP306 outside Greater China. AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving d...